Orally disintegrating donepezil: Are the main caregivers of patients with Alzheimer's disease more satisfied with this formulation of donepezil than with the traditional one?;Donepecilo bucodispersable: ¿están los cuidadores principales del paciente con enfermedad de Alzheimer más satisfechos que con la formulación tradicional de donepecilo?

Revista de Neurologia

Volumn 49, Issue 9, 2009, Pages 451-457

  Sevilla, C ^a   Jiménez Caballero, Pedro E ^b   Alfonso, V ^c  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c European Biometrics Institute   (Spain)

Author keywords

Alzheimer's disease; Caregivers; Donepezil tablets; Orally disintegrating donepezil; SATMED Q; Treatment satisfaction

Indexed keywords

DONEPEZIL; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SELF ADMINISTRATION; FEMALE; FILM COATING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MULTICENTER STUDY; PATIENT SATISFACTION; QUESTIONNAIRE; SCORING SYSTEM; TABLET FORMULATION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; TABLET;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CAREGIVERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INDANS; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PATIENT SATISFACTION; PIPERIDINES; QUESTIONNAIRES; TABLETS; TREATMENT OUTCOME;

EID: 73949102977     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4909.2008615     Document Type: Article

References (48)

1. Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin 2007; 23: 2705-13.
2. Zhou X, Xu J, Zhao Y. Risk factors of distress in Alzheimer's patients. Ann Acad Med Singapore 2007; 36: 253-8.
3. Howden CW. Management of acid-related disorders in patients with dysphagia. Am J Med 2004; 117 (Suppl 5A): S44-8.
4. Eggenberger SK, Nelms TP. Artificial hydration and nutrition in advanced Alzheimer's disease: facilitating family decision-making. J Clin Nurs 2004; 13: 661-7.
5. Botella-Trelis JJ, Ferrero-López MI. Nutrition of Alzheimer's patients in the family setting. Nutr Hosp 2004; 19: 154-9.
6. Travis SS, Bethea LS, Winn P. Medication administration hassles reported by family caregivers of dependent elderly persons. J Gerontol A Biol Sci Med Sci 2000; 55: M412-7.
7. Carnaby-Mann G, Crary M. Pill swallowing by adults with dysphagia. Arch Otolaryngol Head Neck Surg 2005; 131: 970-5.
8. Popa G, Gafitanu E. Oral disintegrating tablets. A new, modern, solid dosage form. Rev Med Chir Soc Med Nat Iasi 2003; 107: 337-42.
9. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000; 10: 195-203.
10. McCarten JR, Rottunda SJ, Kuskowski MA. Change in the Minimental State Exam in Alzheimer's disease over 2 years: the experience of a dementia clinic. J Alzheimers Dis 2004; 6: 11-5.
11. Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, et al. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006; 21: 353-63.
12. Wallin AK, Andreasen N, Eriksson S, Batsman S, Nasman B, Ekdahl A, et al. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord 2007; 23: 150-60.
13. Small GW, Kaufer D, Mendiondo MS, Quarg P, Spiegel R. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005; 59: 473-7.
14. Gillette-Guyonnet S, Andrieu S, Cortes F, Nourhashemi F, Cantet C, Ousset PJ, et al. Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors. J Gerontol A Biol Sci Med Sci 2006; 61: 516-20.
15. Becker M, Andel R, Rohrer L, Banks SM. The effect of cholinesterase inhibitors on risk of nursing home placement among medicaid beneficiaries with dementia. Alzheimer Dis Assoc Disord 2006; 20: 147-52.
16. Sugimoto H, Tsuchiya Y, Sugumi H, Higurashi K, Karibe N, Iimura Y, et al. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-(2-phthalimidoethyl)piperidine and related derivatives. J Med Chem 1992; 35: 4542-8.
17. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-8.
18. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7: 293-303.
19. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021-31.
20. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-45.
21. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, et al. The effects of donepezil in Alzheimer's disease -results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-44.
22. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-95.
23. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. Openlabel, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58: 427-33.
24. López-Pousa S, Robles A, Bermejo F, Masramón X, Rejas J, León T, et al. Resultados del estudio Donald.es: cohorte de pacientes con EA leve a moderadamente grave tratados con donepecilo durante dos años [abstract]. Neurologia 2006; 21: 474-5.
25. Bermejo F, Robles A, López-Pousa S, Masramón X, Rejas J, León T, et al. Calidad de vida (CVRS) en la enfermedad de Alzheimer (EA) y sobrecarga del cuidador en una cohorte de pacientes tratados con donepecilo durante dos años en condiciones de práctica médica habitual: resultados del estudio Donald.es [abstract]. Neurologia 2006; 21: 622.
26. López-Pousa S, Bermejo F, Frank A, Hernández F, León T, Rejas J, y Grupo colaborativo ECO. Efecto del donepecilo frente a otros anticolinesterásicos en la función cognitiva y funcionalidad del paciente en una cohorte prospectiva de pacientes con enfermedad de Alzheimer (EA) tratados en condiciones de práctica médica habitual: subanálisis del estudio naturalístico ECO [abstract]. Neurologia 2007; 22: 809.
27. López-Pousa S, Turón-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, et al. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. Dement Geriatr Cogn Disord 2005; 19: 189-95.
28. Mossello E, Tonon E, Caleri V, Tilli S, Cantini C, Cavallini MC, et al. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a 'real world' study. Arch Gerontol Geriatr Suppl 2004; 297-307.
29. Aguglia E, Onor ML, Saina M, Maso E. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin 2004; 20: 1747-52.
30. Caffarra P, Vezzadini G, Copelli S, Dieci F, Messa G, Nonis E, et al. Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors. Acta Biomed 2007; 78: 16-21.
31. Roe CM, Anderson MJ, Spivack B. How many patients complete an adequate trial of donepezil? Alzheimer Dis Assoc Disord 2002; 16: 49-51.
32. Eisai-Inc. Aricept® (donepezil hydrochloride) tablets and orally disintegrating tablets prescribing information. AHFS Drug Information. URL: http://www.medicinescomplete.com/mc/ahfs/current/a397032.htm.
33. Nakamura Y, Furiya Y, Yoshihino H, Tanioku M, Ueno S, Kishimoto T. Utility of orally disintegrating tablets in patients with Alzheimer-type dementia. J Ger Psychiatr 2006; 17: 332-6.
34. Cleary PD, McNeil BJ. Patient satisfaction as an indicator of quality care. Inquiry 1988; 25: 25-36.
35. Shikiar R, Rentz AM. Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health 2004; 7: 204-15.
36. Ruiz MA, Pardo A, Rejas J, Soto J, Villasante F, Aranguren JL. Development and validation of the 'Treatment Satisfaction with Medicines Questionnaire' (SATMED-Q). Value Health 2008; 11: 913-26.
37. Dowson AJ, Almqvist P. Part III: the convenience of, and patient preference for, zolmitriptan orally disintegrating tablet. Curr Med Res Opin 2005; 21 (Suppl 3): S13-7.
38. Kinon BJ, Hill AL, Liu H, Kollack-Walker S. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int J Neuropsychopharmacol 2003; 6: 97-102.
39. Roose SP. Compliance: the impact of adverse events and tolerability on the physician's treatment decisions. Eur Neuropsychopharmacol 2003; 13 (Suppl 3): S85-92.
40. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). Washington DC: APA; 1994.
41. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
42. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. J Postgrad Med 2002; 48: 206-8.
43. Benoit M, Robert PH, Staccini P, Brocker P, Guerin O, Lechowski L, et al. One-year longitudinal evaluation of neuropsychiatric symptoms in Alzheimer's disease. The REAL.FR Study. J Nutr Health Aging 2005; 9: 95-9.
44. Karlawish JH, Casarett D, Klocinski J, Clark CM. The relationship between caregivers' global ratings of Alzheimer's disease patients' quality of life, disease severity, and the caregiving experience. J Am Geriatr Soc 2001; 49: 1066-70.
45. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2: 12.
46. Peña P, Sancho J, Rufo R, Martínez S, Rejas J. Driving cost factors in adult outpatients with refractory epilepsy: a daily clinical practice in clinics of neurology in Spain. Epilepsy Res 2009; 83: 133-43.
47. López-Pousa S, Garre-Olmo J, Vilalta-Franch J. Galantamina frente a donepecilo en el tratamiento de la enfermedad de Alzheimer. Rev Neurol 2007; 44: 677-84.
48. Gil-Nécija E, Gobart AL, Grupo de investigadores del estudio TRAIN. Patrón de tratamiento de la enfermedad de Alzheimer con inhibidores colinesterásicos (estudio TRAIN). Rev Neurol 2008; 46: 461-4.